Roche’s PD-L1 Bladder Cancer Data Show Promise Of New Biomarkers
Executive Summary
Use of The Cancer Genome Atlas subtyping and mutational load analysis complement PD-L1 expression, with potential to improve prediction of response to atezolizumab in the future, according to study in the Lancet.
You may also be interested in...
Roche's Oncology Strategy: The Long Game Comes Into Focus
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.